Multi-omics analysis powered by massive data integration

Similar documents
Delivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y

Advancing New Treatments for DMD and C. difficile Infection

ataluren overview A New Approach to Genetic Disorders

Muscular Dystrophy Australia. Research RoadShow

Prosensa announces commencement of redosing of drisapersen in North America in patients with Duchenne muscular dystrophy

Prosensa s continued development of exon-51 skipping with drisapersen after the failure of its phase-iii clinical trial.

DUCHENNE MUSCULAR DYSTROPHY CLINICAL DEVELOPMENT PROGRAM

AS91159 Demonstrate understanding of gene expression

BBMRI.NL A story of Sharing Eline Slagboom Molecular Epidemiology, Leiden University Medical Center Brussel 20 Juni 2017

Terminology for personalized medicine

Delivering on the Promise of RNA- Based Therapeu;cs

Exon Skipping. Wendy Erler Patient Advocacy Wave Life Sciences

Drug Development and Clinical Trials Pat Furlong Parent Project Muscular Dystrophy

Recombinant Biglycan for the Treatment! of Duchenne Muscular Dystrophy!!! PPMD Annual Conference, Jun 2013! By Joel B. Braunstein, MD!

Prosensa Therapeutics R&D in ultra-rare disease

PTC Therapeutics: 20 years of commitment to bringing new treatments to patients with rare disorders. March 2018

BIOCRATES Life Sciences AG Short Company Presentation

AGILENT S BIOINFORMATICS ANALYSIS SOFTWARE

Pfizer Program in DMD. Beth Belluscio, MD-Ph.D. Pfizer Rare Disease September 9, 2017

Introduction to Bioinformatics

Preclinical pharmacokinetics and pharmacodynamics of AG-519, an allosteric pyruvate kinase activator

leading the way in research & development

Biomarkers for Delirium

Personalized Medicine

Goals of pharmacogenomics

Emerging Focus. Nutrigenomics. Department of Nutritional Sciences Faculty of Life Sciences

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Clinical trials for skipping exon 51 as a therapy for Duchenne muscular dystrophy.

Forthcoming Calls for Proposals (10/11) Barcelona 28 June 2013

Genes and Proteins in Health. and Disease

Personalized. Health in Canada

Extramural Research Pulmonary Arterial Hypertension. James P. Kiley, M.S., Ph.D. June 20, 2008

Clinician s Guide to Actionable Genes and Genome Interpretation

Impact of Retinoic acid induced-1 (Rai1) on Regulators of Metabolism and Adipogenesis

Department of Neurology. MRC Centre for Translational Research in Neuromuscular Diseases Second Scientific Advisory Board Review 21 st November 2011

Microbial Metabolism Systems Microbiology

"Stratification biomarkers in personalised medicine"

Presentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development

Genentech, Inc., its research partners, collaborators, assignees, licensees or designees. Invitation to Participate

Outline and learning objectives. From Proteomics to Systems Biology. Integration of omics - information

Polypharmacology. Giulio Rastelli Molecular Modelling and Drug Design Lab

Handy Gelbard, Director Professor of Neurology, Pediatrics, Microbiology & Immunology and Neuroscience

COMPASS. Cure SMA Awards 10 New Grants in Basic and Clinical Care Research. A Publication Dedicated to Research Updates SPRING 2016

Introducing a Highly Integrated Approach to Translational Research: Biomarker Data Management, Data Integration, and Collaboration

Decision Process for Committing to a Therapeutic Development Approach: Target Validation Metrics and Biomarkers

Exam MOL3007 Functional Genomics

The 150+ Tomato Genome (re-)sequence Project; Lessons Learned and Potential

Swissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia

CNS Gene Regulation Platform

The connection between genes, proteins and metabolism CAMPBELL BIOLOGY

Multi-omics in biology: integration of omics techniques

Second Quarter 2016 Financial Results. August 4, 2016

The Five Key Elements of a Successful Metabolomics Study

From Variants to Pathways: Agilent GeneSpring GX s Variant Analysis Workflow

TRANSFORMING GLOBAL GENETIC DATA INTO MEDICAL DECISIONS

TOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS

ORPHANET s Services for Researchers. Valérie THIBAUDEAU Database Manager Orphanet

International Conference 2015

The Road to Functional Bioanalysis: Development and Validation of a Cell-Based Assay for Neutralizing Anti-Drug Antibody Analysis

Changes of myocardial gene expression and protein composition in patients with dilated

Implementing the 21 st Century Cures Act: Supporting Orphan Drug Development

Consortia-Based Strategies in Neurodegenerative Diseases: Critical Path Institute s Track Record in Collaborative Efforts

Translational Research

IPA Advanced Training Course

Application of RNA Interference to Anti-Doping. Matthew Fedoruk, Ph.D. Gene & Cell Doping Symposium 2013, Beijing, China

Partnering with Rare Disease Patient Groups. Namrata Taak R&D External Communications, Rare Diseases

NEUROLOGY AND OPHTHALMOLOGY

PMDA s Future Activities

Unit 10: Genetics. Chapter 9: Read P

Smart India Hackathon

Preanalytical Variables in Blood Collection: Impact on Precision Medicine

SYNODOS: A CALL TO ACTION IN THE FIGHT AGAINST SCHWANNOMATOSIS

ENDOGENOUS METABOLIC PROFILING AS A FUNDAMENT FOR PERSONALIZED THERANOSTICS. Torbjörn Lundstedt Professor in Chemometrics C.S.O.

a) JOURNAL OF BIOLOGICAL CHEMISTRY b) PNAS c) NATURE

Knowledge-Guided Analysis with KnowEnG Lab

Building molecular handprints: a systems biology approach to complex diseases

Introduction to Microarray Analysis

Dr. Leslie Hudson President and CEO AVI BioPharma

Accelerating Cures: Addressing Unmet Patient Need Or Putting Patients At Risk? Speaker

TRANSLATIONAL RESEARCH A possible approach for treating FSHD with RNAi therapeutics Perspectives and updates from the FSH Society

Influence of base pair mismatch location on the binding efficiency of nucleotide strands

Navigating the Regulatory Pathway for Genetic Tests and Biomarkers in Clinical Drug Development

Phase 1 Clinical Studies First-In-Human (FIH) <Chapter 31> Pharmacologically-Guided Dose Escalation

New Frontiers in Personalized Medicine

Stefano Monti. Workshop Format

The NHS approach to personalised medicine in respiratory disease. Professor Sue Chief Scientific Officer for England

HD Regulatory Science Consortium (HD-RSC) A consortium aimed at accelerating treatments for Huntington s disease

Bridging the Gap Between Basic and Clinical Research. Julio E. Celis Danish Cancer Society

GUIDANCE ON THE EVALUATION OF NON ACCREDITED QUALIFICATIONS

PXBioVisioN. Protease Inhibition. Analysis of Peptides as Surrogates for Protease Activity to Monitor Protease Inhibition in-vivo

TREAT-NMD Partner Newsletter No th June 2007 and Club of Interest Newsletter No. 8

(51) Int Cl.: C12N 15/11 ( ) A61K 31/7088 ( ) C12N 15/86 ( )

REIMAGINING DRUG DEVELOPMENT:

Application of Deep Learning to Drug Discovery

Neue Technologien für die patientennahe personalisierte Diagnostik

Transcription:

Multi-omics analysis powered by massive data integration RE(ACT) congress 08-02-2018 Kristina Hettne, PhD BioSemantics Group, Human Genetics LEIDEN UNIVERSITY MEDICAL CENTER

Duchenne muscular dystrophy (DMD) X-linked Mutations in dystrophin - in DMD patients dystrophin is virtually absent; Becker muscular dystrophy patients have 10% to 40% of the normal amount Muscle atrophy, inflammation, fibrosis, fat deposits Incidence 1:5000, costs: $80.000 - $120.000 p.p/p.y https://kin450-neurophysiology.wikispaces.com/duchenne+muscular+dystrophy 2

Role of muscle biopsies in clinical trials Muscle biopsies are often requested in interventional clinical trials to show proof of concept that the drug is working e.g. dystrophin restoration after gene therapy, but muscle biopsies are invasive for the patient 3

Can bio-signature detection in blood offer an alternative? Identification of blood biomarkers able to monitor disease progression and response to therapy would enable: Better marketing authorization of medicinal products for DMD and muscular dystrophies in general The analysis of blood should support drug developers to show the drug is working (or not working) without taking muscle biopsies 4

Aim Gain insights into the effect of dystrophin deficiency on a molecular level identification of novel biomarkers for disease severity and progression 5Insert > Header & footer

Research question Identify groups of genes that remain active and drive the pathology 6Insert > Header & footer

Dystrophin-deficient mdx mice - Bred at the LUMC - DMD mouse model Nonsense mutation dystrophin - Capable of producing functional analog Utrophin Less severe symptoms 7 Olga Veth 6/6/17

Experimental design mdx mice: Samples at 6, 12, 18, 24 and 30 weeks of age Sacrifice at week 30 4 groups, 5-6 mouse per group C57BL or hybrid Pietro Spitali 8Insert > Header & footer

Multi-omics data integration, networks and knowledge discovery Problems: Different sizes of data sets Multiple testing burden Solution: Network-based integration Knowledge graphs Rachel Cavill et al. Brief Bioinform, Dec 2015;bib.bbv090 9Insert > Header & footer

Approach mdx study 10 Insert > Header & footer

Weighted correlation network analysis (WGCNA) 1. Calculate co-expression values 2. Cluster co-expression values 3. Relate modules (lists of genes, metabolites or lipids) to genotype, phenotype, or clinical parameters 11 Insert > Header & footer Langfelder and Horvath, 2008

Approach 12 Insert > Header & footer

Transcriptomics modules

Metabolomics modules

Lipidomics modules

Calculate significance Does a module have any relation to the disease? Calculate module eigengenes The first principal component of the standardized expression profiles Module eigengenes not always normally distributed Calculate significance by comparing the group means of the module eigengene values using the parametric Kruskal-Wallis test Significance (p < 0.05) indicates a general difference in expression of the module s molecules between one or more group pairs (e.g. wt vs mdx)

All metabolomics modules significant, all but one lipidomics module, no transcriptomics modules Example: metabolomics eigengene plots mdx+/+ = mdx/utrn+/+ mdx+/- = mdx/utrn+/- Mohammed Charrout

Approach 18 Insert > Header & footer

Cross-correlation between module eigengenes reveals multi-omic correlations Module eigengene: the first principal component of the standardized expression profiles Encircled numbers: significant Red line: positive correlation Blue line: negative correlation Mohammed Charrout

Cross-correlation filtered for three-way omics Red line: positive correlation Blue line: negative correlation Mohammed Charrout

Cross-correlation filtered for three-way omics Turquoise module Highly connected Significant correlations to other omics 0.55 (p=0.01) 0.48 (p=0.04) 0.47 (p=0.04) 0.48 (p=0.04) wt mdx mdx+/+ mdx+/- Red line: positive correlation Blue line: negative correlation mdx+/+ = mdx/utrn+/+ mdx+/- = mdx/utrn+/- Mohammed Charrout

Overlap with longtitudinal proteomics in DMD patients * *Proteins changed over time in serum from DMD patients from Spitali et al. 2018. Under review.

Physiologic functional annotation with Euretos Data Sources: 200+ http://www.euretos.com/files/euretossources2018.pdf Human Protein Atlas Phenotype < > Pathways < > Proteomics < >Metabolomics< > Genetics

Euretos physiologic function annotation reveals annotation overlap cytokine signaling process glucose homeostasis biological adaptation to stress cytoprotection negative regulation of circadian rhythm inhibition of circadian rhythm muscle contraction glucose tolerance activation of phosphoinositide 3-kinase cascade endocrine physiology cardiac muscle hypertrophy in response to stress neutrophil degranulation heterophil degranulation fibrinolysis immunity glucose homeostasis energy metabolism heat-shock response nfat pathway uptake physiologic function 24 Insert > Header & footer

Functional annotation overlap does not have to mean gene overlap 25 Insert > Header & footer

Euretos physiologic function annotation reveals muscle-related processes cytokine signaling process glucose homeostasis biological adaptation to stress cytoprotection negative regulation of circadian rhythm inhibition of circadian rhythm muscle contraction glucose tolerance activation of phosphoinositide 3-kinase cascade endocrine physiology cardiac muscle hypertrophy in response to stress 26 Insert > Header & footer

Digging deeper with gene-disease analysis: SCN4A from muscle contraction process Inspired by: Hettne KM. PLoS One. 2016 Feb. doi:10.1371/journal.pone.0149621. 27 Insert > Header & footer

SCN4A is expressed in healthy muscle 28 Insert > Header & footer

Summary Disease-related biomolecular modules were found in mouse blood metabolomics and lipidomics data Cross-correlation between module eigengenes revealed multi-omic correlations Significantly correlated turquoise transcriptomics module was related to cytokine production, glucose homeostasis and muscle contraction In conclusion: Multi-omics network analysis reveals a muscular dystrophy-related signature in mouse blood

Data management - When published: data in public repositories, scripts on GitHub - Now: - Scripts on LUMC GitLab - Metadata and result data files on FAIR Data Point - WGCNA web tool by Mohammed Charrout creates report with parameters used on GitHub - https://github.com/mochar/wgcna 6/6/17

Next steps Drug repurposing In progress, integrative pipeline to match targets with drugs in place Uptake in the RD-Connect platform Multi-omics analysis pipeline under construction Will incorporate lessons learned from the past years multi-omics analyses: Huntington's Disease (transcriptomics, metabolomics, lipidomics; mouse [1] and human [2]) Duchenne muscular dystrophy (proteomics, transcriptomics, metabolomics, lipidomics; mouse [3] and human [4]) SCA3 (transcriptomics, metabolomics, lipidomics; mouse [5]) Beta-thalassemia (transcriptomics, proteomics, human [6]) [1] Mina E, et al. Orphanet J Rare Dis. 2016 and in preparation. [2] Mastrokolias A, et al. Metabolomics. 2016. PMID: 27524956 [3] Hettne K, et al. in preparation. [4] Spitali P, et al. J Cell Mol Med. 2018 and under review. [5] Toonen L, et al. under review. [6] Katsantoni E, et al. in preparation.

Thank you BioSemantics/Bioinformatics (LUMC) Mohammed Charrout, Eleni Mina, Marco Roos, Mark Thompson, Kees Burger, Rajaram Kaliyaperumal, Barend Mons, Annika Jacobsen Peter A.C. 't Hoen (since Feb 2018 Radboud UMC) DMD exon skip group (LUMC) Pietro Spitali, Annemieke Aartsma-Rus Medical Statistics (LUMC) Roula Tsonaka Profilomic/MedDay Alexandre Seyer 32